Cashu
SELLAS Life Sciences Group: Request for Content to Summarize
about 2 hours ago
Stocks
Health Care
sls
SELLAS Life Sciences Group
NASDAQ: SLS
-0.91 (-18.10%)
4.095
USD
At close at Jan 06, 21:42 UTC
Overview
Loading chart...
Key Stats
Market Cap
526.49M
Dividend Yield
0.00%
P/E Ratio
-20.29
EPS
-0.52
Revenue
-
Avg. Volume
24.83M
About
What does SLS do?
SELLAS Life Sciences Group, a clinical stage biopharmaceutical company based in New York, develops immunotherapeutics for cancer, including galinpepimut-S and SLS009. The company went public in 2008 and employs 16 staff.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.